Protagonist Therapeutics PTGX Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -343.6%-402pp | 58.2%— | —— | -494.2%-34.2pp | |
| Net margin | -282.8%-346pp | 63.3%— | —— | -479.3%-20.3pp | |
| EBITDA margin | -340.9%-399pp | 58.4%— | —— | -490.3%-33.3pp | |
| Returns | |||||
| Return on equity | -20.2%-74.6pp | 54.4%— | —— | -49.4%-6.1pp | |
| Return on assets | -18.4%-68.3pp | 49.9%— | —— | -42.8%-5.4pp | |
| Return on invested capital | -29.1%-96.4pp | 67.3%— | —— | -95.3%-23.5pp | |
| Efficiency | |||||
| Asset turnover | 0.1×-0.7× | 0.8×+0.6× | 0.2×+0.1× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 12.7×+0.2× | 12.5×-4.2× | 16.7×+8.9× | 7.8×+0.1× | |
| Quick ratio | 12.7×+0.2× | 12.5×-4.2× | 16.7×+8.9× | 7.8×+0.1× | |
| Cash ratio | 2.8×+0.8× | 2.1×-6.7× | 8.8×+4.7× | 4×+1.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $9.67-6.8% | $10.38+75.0% | $5.93+34.9% | $4.40-32.1% | |
| Valuation | |||||
| Market capitalization | $5.46B+137% | $2.3B+66.1% | $1.38B+158% | $536.75M-67.1% | |
| Enterprise value | $5.34B+141% | $2.21B+84.6% | $1.2B+189% | $414.67M-72.6% | |
| Price / sales | 118.7×+113× | 5.3×-17.8× | 23.1×+2.9× | 20.2×-39.5× | |
| Price / book | 8.9×+5.5× | 3.4×-0.7× | 4.1×+1.6× | 2.5×-3.0× | |
| EV / sales | 116.1×+111× | 5.1×-14.9× | 20×+4.4× | 15.6×-39.8× | |
| Earnings yield | -2.4%-14.3pp | 12%— | —— | -23.7%-16.0pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Protagonist Therapeutics's ratios come from?
- Every ratio is computed from Protagonist Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
